Nexalin Technology, Inc.

NXL Healthcare Medical Devices

Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.

2.35 0.10 −4.08%
Market cap
$2.6M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
5/9
Altman Z
−26.89
Beneish M
−2.86
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 5 5 5
ROE
(178.46%) (221.50%) (319.69%) (240.25%)
ROA
(167.17%) (185.64%) (252.65%) (187.89%)
ROIC
(1,331.05%) (21,146.42%) (2,987.77%) (1,108.82%)
Return on Tangible Assets
(194.60%) (240.98%) (329.66%) (2,141.72%)
Average Days of Receivables
18.38 98.75 56.95 88.90
Free Cash Flow per Share
(8.48) (9.26) (8.37) (9.00)
Free Cash Flow
(5.02) (5.05) (5.52) (6.34)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026